Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Reaxys User Day 2022: Researcher secrets in the spotlight

Posted on May 26th, 2022 by

In April, Elsevier hosted the first Reaxys User Day to learn from expert users and share best practices. Attendees were also updated on how the expert-curated chemistry database has dramatically upped its ability to streamline R&D. We spoke with senior director Ivan Krstic about how Reaxys is turning data into actionable insights to better understand the competitive landscape, design novel compounds, and generally accelerate synthetic chemistry. “Today is about sharing the amazing strides we’ve made,” says Ivan.

(more…)

Taking on the Net Zero challenge at the government level

Posted on May 24th, 2022 by

Life sciences companies are increasingly committing themselves to Net Zero goals, laying out plans for reaching zero emissions by 2050 or earlier. This is a vitally important step for industry. But national, state and city governments also have a critical role in reducing emissions created by various sectors under their jurisdiction.

(more…)

Pharma’s path to Net Zero

Posted on May 3rd, 2022 by

Pharma is seldom top of mind when thinking about the most polluting industries, but pharmaceutical industry operations are in fact responsible for a significant portion of the world’s greenhouse gas emissions – even rivaling industries that are far more associated with contributing to the problem. 

(more…)

Pharma can now track the most relevant patent info – fast and at scale

Posted on April 26th, 2022 by

Since its initial release in January 2021, AI-fueled Patent Expansion in Reaxys has won the respect of pharmaceutical companies trying to stay ahead of their competitors by keeping track of the latest patents around drug discovery and new therapeutics. With a recent expansion that allows Reaxys to also loop in information from images found in patents, it’s a good time to look back – and forward – at this continual work-in-progress. We spoke to Umesh Nandal, Elsevier’s Director of Data Science, about the logic behind the tech: “It’s not just about the speed of access to all this annotated data, but the quality.”

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 93